Transgene
A clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics.
Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The French company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses.
They include TG4050, the first individualized therapeutic vaccine based on the myvac platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO viral backbone.
Latest Transgene News & Features
23 January 2024
10 February 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze